MARKET

ELDN

ELDN

Eledon Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.32
-0.05
-0.53%
Opening 09:47 05/06 EDT
OPEN
9.32
PREV CLOSE
9.37
HIGH
9.32
LOW
9.32
VOLUME
56
TURNOVER
--
52 WEEK HIGH
27.32
52 WEEK LOW
6.16
MARKET CAP
133.34M
P/E (TTM)
-0.4932
1D
5D
1M
3M
1Y
5Y
Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
IRVINE, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN),...
GlobeNewswire · 17h ago
Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
IRVINE, May 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals ("Eledon") (NASDAQ: ELDN), a...
GlobeNewswire · 1d ago
Eledon Pharmaceuticals (ELDN) Gets a Buy Rating from LifeSci Capital
SmarterAnalyst · 6d ago
Eledon Pharmaceuticals (ELDN) Receives a Buy from Leerink Partners
In a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Eledon Pharmaceuticals (ELDN), with a price target of $33.00.
SmarterAnalyst · 04/27 12:26
Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models
Benzinga · 04/27 11:55
SVB Leerink Maintains Outperform on Eledon Pharmaceuticals, Lowers Price Target to $33
SVB Leerink analyst Thomas Smith maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Outperform and lowers the price target from $34 to $33.
Benzinga · 04/27 10:27
BRIEF-Eledon Pharmaceuticals Inc - Announces Update On Development Strategy For At-1501 In Renal Transplantation
reuters.com · 04/26 20:18
Eledon gives update on development strategy for AT-1501 in renal transplantation
Eledon Pharmaceuticals (ELDN) announced an updated development strategy for AT-1501 in renal transplantation following a request made by the U.S. FDA.The health regulator requested the company to provide AT-1501 specific,
Seekingalpha · 04/26 20:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ELDN. Analyze the recent business situations of Eledon Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ELDN stock price target is 31.67 with a high estimate of 39.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 6.45M
% Owned: 45.11%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
7
601.33K
New
9
4.75M
Decreased
6
3.73M
Sold Out
6
4.93K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.74%
Pharmaceuticals & Medical Research
-1.13%
Key Executives
Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer
Paul Little
Senior Vice President - Finance/Chief Accounting Officer
Jon Kuwahara
Chief Compliance Officer/General Counsel/Secretary
Bryan Smith
Other
Jeff Bornstein
Other
David Hovland
Director
June Lee
Director
John McBride
Independent Director
Gary Lyons
Independent Director
Walter Ogier
No Data
About ELDN
Eledon Pharmaceuticals, Inc., formerly Novus Therapeutics, Inc., is a pharmaceutical company. The Company is focused on developing targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases. The Company’s lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb), designed to target CD40 Ligand (CD40L), a molecule expressed on the surface of human immune system T cells. The central role of CD40/CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation. Blocking the activation of the CD40L pathway ameliorates disease progression and pathology in preclinical models of autoimmunity and prevents acute and long-term allograft transplant rejection in multiple animal species.

Webull offers kinds of Eledon Pharmaceuticals Inc stock information, including NASDAQ:ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.